Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients-Reference-Cited by-同舟云学术

Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients

Published:2022-06-08 Issue: Volume: Page:
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Salerno Sara N.¹^ORCID,Capparelli Edmund V.²,McIlleron Helen³⁴^ORCID,Gerhart Jacqueline G.¹^ORCID,Dumond Julie B.¹^ORCID,Kashuba Angela D. M.¹^ORCID,Denti Paolo³^ORCID,Gonzalez Daniel¹^ORCID

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

2. Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego La Jolla California USA

3. Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa

4. Wellcome Centre for Infectious Diseases Research in Africa Institute of Infectious Disease and Molecular Medicine, University of Cape Town South Africa

Funder

Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Institute of Allergy and Infectious Diseases

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2703

Reference50 articles.

1. World Health Organization.Global tuberculosis report 2017. Accessed January 1 2019.http://apps.who.int/medicinedocs/en/m/abstract/Js23360en/

2. Panel on Antiretroviral Therapy and Medical Management of HIV‐Infec.Guidelines for the use of antiretroviral agents in pediatric HIV infection. Accessed January 1 2019.https://aidsinfo.nih.gov/guidelines

3. U.S.Food and Drug Administration Center for Drug Evaluation and Research.Lopinavir/ritonavir (Kaletra) Clinical pharmacology and biopharmaceutics review. Accessed January 1 2019.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21‐226_Kaletra_biopharmr_P1.pdf

4. Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

5. AbbVie Inc.Kaletra (lopinavir and ritonavir) Prescribing Information. Accessed January 1 2019.https://www.rxabbvie.com/pdf/kaletratabpi.pdf

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir;CPT: Pharmacometrics & Systems Pharmacology;2024-06-20

2. Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians;Pediatric Drugs;2024-05-16

3. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes;Clinical Pharmacology & Therapeutics;2024-03